Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer's Disease (Protocol No. MK-8931-017-10)(Also Known as SCH 900931, P07738)

Trial Profile

A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer's Disease (Protocol No. MK-8931-017-10)(Also Known as SCH 900931, P07738)

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 16 Jul 2019

At a glance

  • Drugs Verubecestat (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms EPOCH
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 17 Mar 2019 This trial has been completed in UK - MHRA (End date-2017-04-14), according to European Clinical Trials Database.
    • 31 Aug 2018 Biomarkers information updated
    • 03 May 2018 This trial was terminated early for futility 50 months after onset, which was within 5 months before its scheduled completion, and after enrollment of the planned patients was complete, according to results published in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top